The role of ASCT2 in tumor growth, namely its association with the inhibition of mTOR pathway, has been observed in breast cancer [113], melanoma [114], hepatoma [81], endometrial carcinoma [31], acute myeloid leukemia [115], gastric cancer [116], and prostate cancer [38], through either lentiviral transduction of a short hairpin RNA (shRNA) against ASCT2 or treatment with ASCT2 inhibitors (benzylserine or GPNA, for example). This evidence concerns the gene SLC1A5 and breast carcinoma.